News

Law firm, Izard Nobel has filed a lawsuit seeking class action status in the US District Court for the District of Massachusetts. The case has been filed on

BioMarin has posted GAAP net income of $1.3m ($0.01 per diluted share) for the second quarter of 2009, compared to GAAP net income of $3.8m ($0.04 per diluted

Almirall has posted net income totalling E103.4m for the first half year 2009, whereas the normalized income reached E89.1m. The company has also reflected a 3.9% rise of

Mylan has reported adjusted diluted EPS as $0.32 and $0.65 for the three and six months ended June 30, 2009, compared to $0.20 and $0.29, respectively for the

Sanofi-aventis and Merck & Co. have signed an agreement under which Merck will sell its 50% interest in the companies’ current animal health joint venture, Merial, to Sanofi-aventis

SOCMA has warned against the health care reform bill. In a letter to House Speaker Nancy Pelosi and House Minority Leader John Boehner, SOCMA asked the lawmakers to

Pfizer and Medivation have initiated the phase 3 trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. The international safety and efficacy trial, known as

Cardium has reported plans to develop a DNA-based orthobiologics product portfolio, based on research and development by Cardium’s Tissue Repair Company. It will initially focus on non-union bone

Genentech has announced the results of its phase III study – CRUISE for Lucentis (ranibizumab injection). Data showed improved vision, as measured by the primary endpoint of mean